Transcatheter Technologies has announced that an independent laboratory has completed advanced wear testing for its Trinity valve prosthesis, which it says far exceeds the minimum testing standards. The company adds that the advanced wear testing of the Trinity transcatheter aortic valve implantation (TAVI) device has already completed 600 million cycles (or an estimated 15 years of durability testing).
A press release reports that Transcatheter Technologies previously announced the successful 30-day follow-up results of a pilot study of its Trinity TAVI system, which is designed to be the world’s first ‘”truly repositionable” TAVI system.
“Unlike second-generation TAVI systems, the Trinity aortic valve is designed to be positioned precisely or repositioned, even after full implantation, in a safe and simple manner,” said principal investigator Christian Hengstenberg, a cardiologist at the German Heart Center, Munich, Germany. “In our study, Trinity’s novel sealing cuff continues to provide outstanding follow-up results without paravalvular leak. Equally important, the Trinity aortic valve is designed to reduce the risk of atrio-ventricular block significantly through supra-annular positioning of the Trinity valve.”